Q2 2022 Earnings Forecast for Glaukos Co. (NYSE:GKOS) Issued By William Blair

Glaukos Co. (NYSE:GKOSGet Rating) – William Blair lifted their Q2 2022 EPS estimates for shares of Glaukos in a research note issued on Wednesday, May 11th. William Blair analyst A. Brackmann now forecasts that the medical instruments supplier will post earnings of ($0.46) per share for the quarter, up from their prior estimate of ($0.53). William Blair has a “Outperform” rating on the stock. William Blair also issued estimates for Glaukos’ Q4 2022 earnings at ($0.49) EPS, FY2022 earnings at ($1.85) EPS, Q1 2023 earnings at ($0.50) EPS, Q2 2023 earnings at ($0.42) EPS, Q4 2023 earnings at ($0.36) EPS and FY2023 earnings at ($1.73) EPS.

A number of other brokerages have also recently issued reports on GKOS. Wells Fargo & Company upgraded shares of Glaukos from an “underweight” rating to an “equal weight” rating and set a $56.00 target price for the company in a research report on Wednesday, January 19th. BTIG Research lifted their target price on shares of Glaukos from $61.00 to $66.00 in a research report on Monday, April 18th. StockNews.com assumed coverage on shares of Glaukos in a research report on Thursday, March 31st. They set a “hold” rating for the company. Finally, Citigroup lifted their target price on shares of Glaukos from $49.00 to $55.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 23rd. One research analyst has rated the stock with a sell rating, six have given a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $59.89.

Shares of GKOS opened at $38.63 on Monday. The company has a current ratio of 8.84, a quick ratio of 8.39 and a debt-to-equity ratio of 0.59. The stock has a market cap of $1.83 billion, a P/E ratio of -63.33 and a beta of 1.52. The company has a 50-day moving average of $53.46 and a two-hundred day moving average of $50.77. Glaukos has a 12-month low of $33.33 and a 12-month high of $87.24.

Glaukos (NYSE:GKOSGet Rating) last announced its quarterly earnings data on Wednesday, May 4th. The medical instruments supplier reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.51) by $0.13. Glaukos had a negative net margin of 9.45% and a negative return on equity of 7.95%. The firm had revenue of $67.70 million during the quarter, compared to analysts’ expectations of $60.85 million. During the same quarter last year, the business earned ($0.21) earnings per share. The business’s revenue for the quarter was down .4% compared to the same quarter last year.

Institutional investors have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp grew its holdings in Glaukos by 1.3% in the third quarter. Bank of New York Mellon Corp now owns 465,592 shares of the medical instruments supplier’s stock valued at $22,427,000 after purchasing an additional 6,104 shares during the period. AlphaCrest Capital Management LLC grew its holdings in Glaukos by 130.0% in the fourth quarter. AlphaCrest Capital Management LLC now owns 30,901 shares of the medical instruments supplier’s stock valued at $1,373,000 after purchasing an additional 17,468 shares during the period. Primecap Management Co. CA grew its holdings in Glaukos by 12.5% in the third quarter. Primecap Management Co. CA now owns 500,200 shares of the medical instruments supplier’s stock valued at $24,095,000 after purchasing an additional 55,700 shares during the period. Yousif Capital Management LLC purchased a new stake in Glaukos in the fourth quarter valued at approximately $1,866,000. Finally, Maryland State Retirement & Pension System lifted its position in Glaukos by 2.0% during the fourth quarter. Maryland State Retirement & Pension System now owns 18,693 shares of the medical instruments supplier’s stock valued at $831,000 after buying an additional 372 shares in the last quarter. Hedge funds and other institutional investors own 92.52% of the company’s stock.

About Glaukos (Get Rating)

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.

Featured Articles

Earnings History and Estimates for Glaukos (NYSE:GKOS)

Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.